Bronconex Acticap

New Zealand - English - Medsafe (Medicines Safety Authority)

Buy It Now

Active ingredient:
Mometasone furoate 400 µg (anhydrous)
Available from:
Merck Sharp & Dohme (New Zealand) Limited
INN (International Name):
Mometasone furoate 400 µg (anhydrous)
Dosage:
400 mcg/dose
Pharmaceutical form:
Powder for inhalation
Composition:
Active: Mometasone furoate 400 µg (anhydrous) Excipient: Lactose
Units in package:
Inhaler, metered, DPI, (sample), 14 dose units
Class:
Prescription
Prescription type:
Prescription
Manufactured by:
MSD International GmbH (Singapore Branch)
Therapeutic indications:
Bronconex Acticap is indicated for prophylactic therapy in the management of patients with asthma of all severities, including patients who have been dependent upon either inhaled or systemically administered corticosteroids and non-corticosteroid-dependent patients inadequately controlled on other drug regimens.
Product summary:
Package - Contents - Shelf Life: Inhaler, metered, DPI, (sample) - 14 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 30 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 60 dose units - 18 months from date of manufacture stored at or below 25°C
Authorization number:
TT50-6670a
Authorization date:
2000-12-05

Similar products

Search alerts related to this product

Share this information